Skip to main content

Market Overview

Read Why Lexaria Bioscience Shares Are Surging During Wednesday Premarket?

Share:
Read Why Lexaria Bioscience Shares Are Surging During Wednesday Premarket?

Lexaria Bioscience Corp (NASDAQ: LEXX) has issued follow-up results from human clinical study HYPER-H21-2 of DehydraTECH-processed cannabidiol (CBD).

  • The data showed that after a single day of dosing, the processed CBD reduced arterial stiffness, potentially broadening its application to the treatment of cardiovascular and other disease states beyond hypertension.
  • Related Link: Lexaria Starts IND-Enabling Program For DehydraTECH-CBD For Hypertension.
  • Arterial stiffness can also be a prognostic marker for cardiovascular events and all-cause mortality, even in asymptomatic individuals without overt cardiovascular disease.
  • Arterial stiffness was measured through pulse wave velocity (PWV) evaluation, together with assessments of augmentation index and pressure. 
  • All comparisons between DehydraTECH-CBD and placebo were statistically significant (p < 0.01).
  • Related Link: Lexaria Announces DehydraTECH-CBD Versus Prescription CBD Program In Treating Seizures.
  • Price Action: LEXX shares are up 14.20% at $5.62 during the premarket session on the last check Wednesday.
 

Related Articles (LEXX)

View Comments and Join the Discussion!

Posted-In: Biotech Long Ideas News Penny Stocks Health Care Movers Trading Ideas General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com